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Background/aim: The lipid storage myopathy (LSM) diagnosis is based on the patient’s clinical manifestations and muscle pathology.
However, when genetic testing is lacking, there is a high rate of misdiagnosis of the disease. This study aimed to investigate the clinical
and pathological features of genetically diagnosed LSM in northern China, analyze genetic mutations’ characteristics, and improve the
LSM diagnostic rate.
Materials and methods: Twenty patients with LSM diagnosed were collected; meanwhile, the clinical data, muscle samples, and routine
pathological staining of muscle specimens were collected. The morphological changes of muscle fibers were observed under an optical
microscope.
Results: Among the included patients, 18 cases had ETFDH (HGNC ID: 3483) mutations, and two had PNPLA2 mutations. Family
pedigree verification was performed on three patients with heterozygous mutations in the ETFDH gene complex. Histopathological
staining showed that all patients had fine vacuoles in the muscle fibers, and some of them merged to form fissures, and the lipid droplets
increased in cells. After therapy, 18 patients were associated with a favorable prognosis, and two patients were ineffective with the
treatment of neutral lipid storage myopathy (NLSDM) caused by PNPLA2 mutation.
Conclusion: The clinical manifestations of LSM are complex and diverse, mainly manifested by proximal muscle weakness and exercise
intolerance in the extremities. The pathological images of LSM muscles are abnormal storage of lipid droplets in muscle fibers, primarily
involving type I fibers. The LSM patients were mainly multiple acyl-CoA dehydrogenase deficiency (MADD) caused by the ETFDH gene
mutation. It is necessary to perform an accurate typing diagnosis of LSM.
Key words: Lipid storage myopathy, clinical manifestation, pathological staining, gene mutation, ETFDH

1. Introduction
Lipid storage myopathy (LSM) is a group of autosomal
recessive myopathy caused by abnormal fat metabolism,
characterized by abnormal fat storage of intramuscular
fiber [1, 2]. The clinical manifestations of LSM are
complex and diverse. Its main manifestations are volatility
or progressive proximal muscle weakness, exercise
intolerance, and rhabdomyolysis, involving multiple
systems, such as the heart, liver, and kidney [3–5].
The leading causes of LSM include primary carnitine
deficiency (PCD), multiple acyl-CoA dehydrogenase
deficiency (MADD), neutral lipid storage diseases with
ichthyosis (NLSDI), and neutral lipid storage diseases
with myopathy (NLSDM). Multiple mutation genes, such

as SLC22A5, ETFA/B, ETFDH, ABHD5, and PNPLA2,
are involved [6,7]. The ETFDH gene encodes the electron
transfer flavoprotein-ubiquinone oxidoreductase (ETF:
QO); the primary function of this protein is to transfer
electrons carried by ETF to coenzyme Q10 after redox,
enter the mitochondrial oxidation respiratory chain,
and finally be used for the production of ATP [8]. The
ETFDH gene mutations cause short ETF: QO enzyme
activity, which can cause damage the process of electron
transfer to the respiratory chain. Subsequently, it
further causes flavin protein-dependent dehydrogenase
dysfunction and leads to insufficient energy production
and fatty acid accumulation in muscle cells. Electrons
leak into the mitochondrial matrix, forming many
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reactive oxygen species (ROS) in the cell; in turn, ROS
induce abnormal oxidative stress in the cell, affecting
the function and structure of mitochondria [9]. The
patatin-like phospholipase domain-containing protein 2
(PNPLA2) gene mutations cause NLSDM [10]. Peripheral
blood smears in patients with NLSDM showed fat
droplets (Jordan bodies) in multinucleated granulocytes.
The PNPLA2 gene encodes adipose triglyceride lipase
(ATGL), the rate-limiting enzyme of the fat mobilization
pathway. The primary function of ATGL is to hydrolyze
triglycerides (TG) into triglycerides and free fatty acids
[11]. The PNPLA2 gene mutations lead to insufficient
ATGL enzyme activity, causing TG breakdown and
deposition in different tissues and cells, leading to an
inadequate supply of intracellular energy [12].
Studies found that the riboflavin (vitamin B2)
responsive multiple acyl-CoA dehydrogenase deficiencies
(RR-MADD) caused by ETFDH mutation and the
clinical symptoms of patients treated with riboflavin can
be significantly improved [13,14]. Although research
on the genetic diagnosis of LSM has been carried out,
understanding the disease is still insufficient [15].
Currently, most clinicians only confirm the diagnosis of
LSM based on the patient’s clinical manifestations and
combined with muscle pathology. However, the level
of biochemical and molecular diagnosis of LSM has not
improved, and the clinical misdiagnosis rate of patients is
high [16]. Therefore, an accurate classification diagnosis of
LSM patients is necessary to guide clinical treatment.
This study aims to investigate the clinical and
pathological features of genetically diagnosed LSM
patients in northern China and try to provide a theoretical
basis for the diagnosis of LSM.
2. Materials and methods
2.1. Patient’s selection
Twenty patients with LSM diagnosed by muscle pathology
and gene detection were collected from the Second
Hospital of Hebei Medical University from January
2005 to December 2017. The patient’s clinical data were
collected, including gender, age, first symptoms, limb
muscle strength, system involvement, laboratory tests, and
electromyography detection. In this article, the patients
were given fresh morning urine, sent for organic acid
analysis; and three drops of venous blood were taken for
amino acid and acylcarnitine analysis of genetic metabolic
diseases. This study was reviewed by the Ethics Committee
of The Second Hospital of Hebei Medical University. All
patients signed an informed consent form and underwent
open muscle biopsy under local anesthesia.
2.2. Acquisition and processing of muscle specimens
After the patients and their families agreed and signed
the informed consent form, the open muscle biopsy

was performed under local anesthesia. The surgical
site includes the biceps, deltoid, quadriceps, or
gastrocnemius. The fresh muscle specimens were taken
for embedding and quickly frozen in liquid nitrogen
precooled isopentane. The frozen muscle specimens were
placed in a cryostat at –22 °C, and rewarmed for about
30 min to make frozen sections with a thickness of 8μm.
The remaining samples were stored in a –80 °C ultra-low
temperature freezer.
The disease’s diagnosis includes: (1) Muscle biopsy
reveals many lipid droplets in muscle fibers and excludes
secondary muscle fat deposits such as mitochondrial
myopathy and steroid myopathy. (2) There is no
prominent lipid droplet deposition in muscle pathology.
Still, genetic examination results suggest that acyl-CoA
dehydrogenase, very long chain (ACADVL, HGNC: 92),
or carnitine palmitoyltransferase II deficiency (CPT-2,
HGNC: 2330) gene mutation.
2.3. Specimen acquisition and genetic testing
We recorded each patient’s family history in detail and
queried the mutation information based on the database
for Human Gene Mutation Database (HGMD), ESP,
1000g, and ExAC. Protein function was predicted using
comprehensive bioinformatics protein function prediction
software such as REVEL, SIFT, PolyPhen_2, Mutation
Taster, and GERP+. The pathogenicity of de novo mutations
was finally analyzed, relying on family validation and the
2015 ACMG guidelines. All the included LSM patients
received 2mL of peripheral venous blood, which was used
for next-generation sequencing analysis.
2.4. Pathological staining for muscle specimens
Frozen sections were stained with hematoxylin-eosin
(HE) staining, Oil-Red-O (ORO) staining, Modified
Gomori Trichrome (MGT) staining, NADH-tetrazolium
reductase (NADH-TR) staining, succinate dehydrogenase
(SDH) staining, nonspecific esterase (NSE) staining,
adenosine triphosphatase (ATPase, pH 4.5, pH 10.2)
staining, and periodic acid-Schiff (PAS) staining. The
morphological changes in muscle fibers were observed
under a light microscope.
2.5. Statistical methods
Data statistics processing was performed using SPSS 21.0
software. Measurement data were expressed as mean ±
standard deviation (X ± SD). The 25% and 75% intervals of
the median and interquartile intervals describe nonnormally
distributed data. Count data were expressed as the number
of observed indicators and the percentage of the total. The
t-test was used for two-way comparisons of measures that
conformed to a normal distribution; the nonparametric test
was used for two-way comparisons of measures that did not
conform to a normal distribution. A statistically significant
difference was considered as p < 0.05.
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3. Results
3.1. Genetic test
Among the 20 patients, 18 (90%) of the ETFDH gene
mutations were carried out, and 2 (10%) of the PNPLA2
gene mutations were held. Fourteen patients had a biallelic
mutation in the ETFDH gene, two patients had mutations
in the ETFDH gene, two patients had mutations in the
ETFA and ETFDH genes, one patient had a homozygous
mutation in the PNPLA2 (HGNC:30802) gene, and one
patient had a mutation in the PNPLA2 gene (Table 1).
Family pedigree verification was performed on three
patients with compound heterozygous mutations in the
ETFDH gene. The result shows that two ETFDH gene
mutations were from both parents; one patient’s parents
had died, the children of the patients carried different
ETFDH genes, and the genetic pattern was consistent with
autosomal recessive inheritance.
3.2. Clinical features of patients with LSM
3.2.1. Demographic characteristics
Among the 20 patients, ten were male (50%). The age range
of onset was 8–48 years old. There is no difference between
men and women in the period of illness (p = 0.715). The
patient’s age of onset is concentrated between 10–30 years
old, accounting for 63.1% (12/19) (Figure 1). The patients
in the article on LSM were insidious onset, with a chronic
disease course ranging from 1 to 7 years (Table 2).
3.2.2. Patient’s course and family history
All patients were occult seizures, with a chronic course
ranging from one month to seven years. There were three
(15%) family history cases among the patients; 17 (85%)
were sporadic cases.
3.2.3. First symptoms
In the patients, there have eight cases with lower extremity
weakness (8/20, 40%), seven cases with limb weakness
(7/20, 35%), three cases with upper limb weakness (3/20,
15%), and one case with poor appetite (1/20, 5%) (Table 2).
3.2.4. Important symptoms with diagnostic value
In all included patients, there have 12 cases with exercise
intolerance (12/20, 60%), six cases with masticatory
muscle weakness (6/20, 30%), two cases with dysphagia
(2/20, 10%), two cases with respiratory muscle weakness
(2/20, 10%), and six cases with myalgia (6/20, 30%). The
significant signs of diagnostic value included 16 (16/20,
80%) cases with decreased muscle strength and five (5/20,
25%) cases with weakness when lifting their head. In the
patients with muscle weakness, there are 15 cases with
symmetric (15/20, 85%), two cases with asymmetric (2/20,
10%), 11 cases with proximal weakness (11/20, 55%), one
case with distal weakness (1/20, 5%), seven cases with
proximal and distal weakness (7/20, 35%), and one case
with normal function (1/20, 5%) (Table 2).

1258

3.2.5. Predisposing factors
Ten patients had clear induced aggravation factors: six
cases were fatigue, two cases were infected, one case was
caught a cold, and one case was due to fast. Other system
involvement, including five cases with heart involvement
(5/20, 25%), mainly manifested as sinus tachycardia.
The digestive system involved five patients (5/20, 25%),
primarily manifested as nausea and vomiting (Table 2).
3.3. Laboratory diagnosis results
3.3.1. Serum CK and uric acid
The study’s serum creatine kinase (CK) value was detected
in 19 patients; among the patients, 17 cases had an increase
(17/19, 89.5%), with a mean of 3753.71 ± 6156.26 U/L
(The normal reference range of serum CK is 18.0–198U/
L). Ten uric acid cases were detected, and 8 cases (80%) of
patients with uric acid were found to have an average value
of 655.30 ± 351.80 U/L (normal blood uric acid: 149–416
μmol/L for adult males; 89–357 μmol/L for females) (Table
2).
3.3.2. Electromyography
In this study, electromyography showed normal in 5
patients (31.25%, 5/16), myogenic injury in 10 (62.5%,
10/16) patients, and neurogenic injury in 5 (31.25%, 5/16)
patients (Table 2).
3.3.3. Urine analysis
A total of six patients were screened for blood and urine
metabolism in this study. Three patients showed glutaric
aciduria, one patient had increased multiple lipoylcarnitine
(C8–C16) in blood, and two patients did not show any
significant abnormalities (Table 2).
3.3.4. Histopathological staining
All patients observed small vacuoles in the muscle
fibers, and some merged to form fissures. Muscle fibers
appeared as fissures or fine vacuoles in hematoxylineosin (HE) staining, with a marked increase in lipid
droplets in ORO staining (Figures 2A, 2B). The SDH
staining results of seven patients showed that the oxidase
distribution of some muscle fibers was uneven, the edges
were intensely stained, or the oxidase was partially
atrophied. The muscle fibers were deeply stained (Figure
2C). In eight patients, the vacuolar-like muscle fibers
were mainly typed I; in 12 cases, both muscle fibers
showed an abnormal increase in lipid droplets (Figures
2D–2G). NADH-TR staining in nine patients showed an
uneven distribution of oxidases in some muscle fibers
and deep staining at the edges or partially atrophic
muscle fibers (Figure 2H).
3.4. Treatment and prognosis
All patients were given riboflavin (30–120 mg/d) +
coenzyme Q10 (150–500 mg/d) + carnitine treatment.
After 7 to 14 days of treatment, the clinical symptoms
began to improve in 18 (90%) patients with a more
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favourable prognosis. After 1 to 1.5 months, patients’
muscle strength was significantly recovered; after 1 to 3
months, most patients’ physical labour or exercise ability
returned to normal, and a few patients still do not tolerate
high-intensity physical activity. However, the treatment
with NLSDM patients caused by PNPLA2 mutation was
ineffective (2/20). Blood uric acid levels decreased to
varying degrees, and six patients (6/10) returned normal.

Two patients underwent a review of muscle pathology after
treatment and found that the muscle fibers’ lipid droplets
decreased or even disappeared. After one year of followup, most patients were given riboflavin for three months
and discontinued without recurrence. Two patients may
experience muscle weakness after infection or fatigue,
and the symptoms may be relieved after riboflavin
supplementation.

Figure 1. The onset age distribution of LSM patients.

Figure 2. The results of characteristic histologic. (A)
Hematoxylin-eosin staining in standard control (200×); (B)
Oil-Red-O staining in standard control (200×); (C) Succinate
dehydrogenase staining in vacuolar muscle fibers and many
atrophic fibers (200×); (D) Acid phosphatase staining in lipid
droplets storage of the myofibers (200×); (E) ATPase staining
in the vacuolated appearance of predominantly type 1 muscle
fibers (PH = 4.5, 200×); (F) Nonspecific esterase staining in
deeply stained in atrophic and degenerative muscle fibers (200×);
(G) Modified-Gomori-Trichrome staining in ragged red fiber
(400×); (H) Nicotinamide adenine dinucleotide staining in
deeply stained in atrophic and degenerative muscle fibers (400×).

1259

HAN et al. / Turk J Med Sci
Table 1. Summary of gene mutations related to LSM.
Gene

Exon

Nucleotide change

Amino acid change

Hom/Het

ETFDH

exon3

c.250G > A

p.A84T

het

ETFDH

exon12

c.1531G > A

p.D511N

het

ETFDH

exon7

c.770A > G

p.Y257C

het

ETFDH※

exon12

c.1534G > A

p.G512R

het

ETFDH※

exon12

c.1552C > G

p.L518

het

ETFDH

exon7

c.770A > G

p.Y257C

het

ETFDH

exon12

c.1531G > A

p.D511N

het

ETFDH

exon3

c.380T > G

p.L127R

het

ETFDH

exon10

c.1227A > C

p.L409F

het

ETFDH※

exon3

c.176-1G > A

Splicing

het

ETFDH

exon10

c.1211T > C

p.M404T

het

ETFDH

exon10

c.1227A > C

p.L409F

het

ETFDH

exon11

c.1395T > G

p.Y465X

het

ETFDH

exon3

c.389A > T

p.D130V

het

ETFDH※

exon10

c.1123C > A

p.P375T

het

ETFDH

exon2

?

ETFDH

exon10

c.1227A > C

ETFDH

exon10

c.1281-1282delAA

ETFDH

exon3

c.389A > T

p.D130V

het

ETFDH※

exon10

c.1285+2T > C

Splicing

het

ETFDH

exon10

c.1211T > C

p.M404T

het

ETFDH※

Exon 1-5

Lose

ETFDH

exon1

c.67G > A

p.A23T

het

ETFDH

exon5

c.587A > G

p.Y196C

het

ETFDH※

exon10

c.1351G > A

p.G451R

het

PNPLA2

exon6

c.757+1G > T

Splicing

hom

ETFDH

exon3

c.250G > A

p.A84T

het

ETFDH※

exon5

c.511A > G

p.N171D

het

ETFDH※

exon4

c.470C > T

p.P157L

het

ETFDH

exon7

c.770A > G

p.Y257C

het

ETFDH

exon7

c.770A > G

p.Y257C

het

ETFDH

exon10

c.1227A > C

p.L409F

het

16

ETFDH

exon5

c.524G > A

p.R175H

het

17

PNPLA2※

exon7

c.863C > G

p.S288W

het

ETFA※

exon8

c.649A > G

p.T217A

het

ETFDH※

exon10

c.1285+1G > A

Splicing

het

ETFA※

exon8

c.649A > G

p.T217A

het

ETFDH※

exon10

c.1285+1G > A

Splicing

het

ETFDH

exon13

c.1691-3C > G

Splicing

het

NO.
1

2

3
4
5
6
7

8

9
10

11
12
13
14
15

18
19
20

het
p.L409F

het
het

het

Het: heterozygote; HOM: homozygote; ※: Novel mutations; ?: Unknown mutation because of information absence.
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Table 2. The clinical findings, symptoms, and laboratory findings.
Factor

Patients (n = 20)

Mean ± SD

Demographic characteristics
Gender (male/female)

10/10 (50%)

Age (years)

8–48

Medical history

3/20 (15.0%)

Course of disease

1m–7y

Family medical history

3/20 (15.0%)

Sporadic case

17/20 (85.0%)

Chronic course of disease (years)

1–7

26.1 ± 2.9

Cardinal symptom
Lower extremity weakness

8/20 (40.0%)

Limb weakness

7/20 (35.0%)

Upper limb weakness

3/20 (15.0%)

Poor appetite

1/20 (5.0%)

Exercise intolerance

12/20 (60.0%)

Masticatory muscle weakness

6/20 (30.0%)

Dysphagia

2/20 (10.0%)

Respiratory muscle weakness

2/20 (10.0%)

Myalgia

6/20 (30.0%)

Decreased muscle strength

16/20 (80.0%)

Weakness when lifting the head

5/20 (25.0%)

Symmetrical muscle weakness

15/20 (75.0%)

Asymmetric muscle weakness

2/20 (10.0%)

Proximal muscle weakness

11/20 (55.0%)

Distal weakness

1/20 (5.0%)

proximal and distal weakness

7/20 (35.0%)

Sinus tachycardia

5/20 (25%)

Nausea and vomiting

5/20 (25%)

Inducing factor
Fatigue

6/20 (30.0%)

Infected

2/20 (10.0%)

Catch a cold

1/20 (5.0%)

Abrosia

1/20 (5.0%)

Laboratory testing
Serum creatine kinase elevated

17/19 (89.5%)

3753.71 ± 6156.26 U/L

Uric acid elevated

8/10 (40.0%)

655.30 ± 351.80 U/L

Electromyography
Myogenic damage

10/16 (62.5%)

Neurogenic damage

5/16 (31.3%)

Blood and urine metabolic screening
Glutaric aciduria

3/6 (50.0%)

Increased lipoylcarnitine

1/6 (16.7%)
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4. Discussion
The disease of LSM can occur at any age, characterized by
occult onset. In this study, 20 LSM patients were collected,
the incidence rate of males and females was 1:1, and the
age of onset was 8–59 years old, with an average of 26.05
± 13.71 years old. The normal life of all patients can be
affected, and most concentrated in 10–30 years old.
The clinical manifestations of LSM are complex and
diverse, mainly manifested as volatility or progressive
proximal muscle weakness and exercise intolerance [17,
18]. The LSM patients were insidious onset, with a chronic
disease course ranging from 1 to 7 years. Generally, the
first symptom in patients was mainly proximal muscle
weakness. Elevated muscle enzymes and anorexia are
relatively rare early symptoms in patients. The muscle
weakness symptoms were symmetrical; only two patients
had asymmetric muscle weakness. All of them were
NLSDM caused by PNPLA2 mutation, suggesting that
the clinical manifestations were asymmetrical muscle
weakness and the muscle pathology was intramuscular fat
storage. These two patients need to consider the possibility
of NLSDM. The symptoms of muscle weakness in patients
with LSM are often fluctuating, aggravated by the inability
to resolve symptoms after exercise. In half of the patients,
muscle weakness symptoms are aggravated under stress
conditions such as infection, fatigue, cold, and hunger;
thus, the lifestyle intervention for LSM patients is equally
important. Long-term use of low-dose riboflavin can avoid
the recurrence of the symptoms, such as muscle weakness.
The LSM patients had mild to moderate elevation of
muscle enzymes and an increasing trend of CK. Most
patients in this group had elevated serum CK levels, with
soft to medium height, suggesting damage to muscle cells.
In addition to muscle involvement performance, LSM
patients may be linked to multiple system involvement
[19, 20]. In this article, five subjects had sinus tachycardia,
and rare T-wave changes were observed. A few patients
start with gastrointestinal symptoms such as nausea
and vomiting, which may be related to lipid storage in
gastrointestinal mucosal, or a metabolic disorder may have
occurred [20, 21]. Most patients with elevated uric acid may
be associated with the following causes: 1. Muscle exercise
caused elevated purine metabolite concentrations in the
plasma by increasing the flow of purine nucleotides from
muscle tissue to plasma, leading to hyperuricemia due to
increased uric acid synthesis (myogenic hyperuricemia)
[22]; 2. Other organic acids in the body, such as lactic acid,
pyruvic acid, etc., inhibit the secretion of uric acid by the
renal tubules, resulting in reduced uric acid excretion [23].
Blood and urine organic acid tests in six patients with LSM
showed that three patients developed urinary symptoms
of increased type 2 plus type 3 hydroxyglutaric acid.
Besides, RR-MADD is often combined with an increase
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in blood organic acid content, indicating the existence of
organic acids that interfere with the possibility of uric acid
excretion. However, patients with non-RR-MADD also
have elevated uric acid, suggesting that other pathways lead
to elevated uric acid that requires further investigation.
Electromyography provides an essential basis for the
diagnosis of muscle disease. LSM electromyography is
mainly characterized by myogenic damage, but individual
patients may also have neurogenic damage or mixed. The
electromyography of this group of patients met the above
characteristics.
Muscle biopsy is an essential means of diagnosing
LSM. LSM muscle pathology is characterized by abnormal
storage of lipid droplets in muscle fibers, mainly involving
type I fibers [24]. Many small circular vacuoles can be seen
in the HE-stained muscle fibers. In severe cases, the fused
large vacuoles can be seen, and the muscle fibers have a
broken appearance. ORO staining shows that the vacuoles
in the muscle fibers are fat deposits, and both types of
muscle fibers can be involved, with type I muscle fibers.
However, LSM exact typing needs to rely on genetic testing
[25]. The ETFDH gene consists of 13 exons and encodes 617
amino acids, including the FAD and ubiquinone domains.
Most of the mutations are found in the FAD domain [26,
27]. The most common mutations in the ETFDH gene in
this group were c.770A > G and c.1227A > C, and at least
one mutation site was located in the FAD domain, which
was consistent with the diagnosis of RR-MADD. After
repeated treatment with riboflavin and coenzyme Q10
in patients with RR-MADD, the clinical symptoms were
significantly improved. This study is similar to Juan Wang et
al. use of the same method in a case report to treat patients
with RR-MADD with ETFDH mutations to achieve
equivalent therapeutic effects. However, the measurement
and method of using coenzyme Q10 are different from
this study [28]. Some patients reviewed muscle pathology
and found that the muscle fibers’ lipid droplets decreased
or even disappeared. LSM caused by primary carnitine
deficiency is a lipodystrophy myopathy with fatigue and
muscle weakness as the primary clinical manifestations.
The pathological changes mainly accumulate lipid droplets
in muscle fibers, which generally do not cause apparent
mitochondrial structure abnormal. In this study, medical
staff should promptly supplement carnitine with muscle
weakness during patients’ treatment. Later, the patient’s
weakness gradually improved. However, the clinical
symptoms of LSM patients treated with oral carnitine can
be moderately improved or ultimately return to normal.
However, this treatment method does not supplement
muscle carnitine storage, and we recommend it as an
adjuvant treatment for patients with LSM [25, 29].
The disease of LSM is an autosomal recessive
inheritance. From a genetic point of view, a homozygous
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mutation or a compound heterozygous mutation can cause
disease. A patient with a single heterozygous mutation is a
gene carrier and does not cause disease. In this article, five
patients were single heterozygous mutations, combined
with their clinical manifestations and pathological
features consistent with LSM diagnosis. Four patients
with ETFDH gene mutations were relieved of muscle
weakness after vitamin B2, considering LSM diagnosis
precise. Similar reports have been reported for patients
with a single heterozygous mutation [27], considering that
the alleles of the possible mutation sites are incompletely
inactivated, that the mutation site is located outside the
exon, or that we are unknown. Other types of mutations
are for further study.
5. Conclusion
The clinical LSM patients presenting multiple
manifestations, mainly proximal limb muscle weakness and
exercise intolerance, may be associated with trunk muscle
weakness and numerous systems. CK increased to varying
degrees, combined with elevated uric acid. LSM muscle

pathology is abnormal storage of lipid droplets in muscle
fibers, mainly involving type I fibers. The LSM patients in
this group are mainly MADD caused by mutation of the
ETFDH gene. The most common mutations are c.770A >
G and c.1227A > C. RR-MADD has a good prognosis, so
it is necessary to perform an accurate typing diagnosis of
LSM.
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